Zhang Li-Jia, Liu Dun, Xu Li-Qing, Wei Jin-Yan, Fan Lin, Zhang Xi-Qian, Liu Feng-Hua
Department of Reproductive Medical Center, Guangdong Women and Children Hospital, Guangzhou, Guangdong Province, China.
Endocr Metab Immune Disord Drug Targets. 2025;25(5):400-410. doi: 10.2174/0118715303281640240722070348.
The aim of the study was to explore the optimal timing of gonadotropin initiation and the reasonable interval of luteinizing hormone (LH) level in the gonadotropin-releasing hormone antagonist (GnRH-A) protocol.
A retrospective cohort study was conducted to analyze the LH level in patients with different ovarian response treated in GnRH-A protocol in 1361 IVF/ICSI cycles. Ovarian response (including AMH, AFC) in these patients were divided into the poor ovarian response group (an antral follicle count (AFC) ≤ 6, n = 394), the normal ovarian response group (an AFC > 6 and < 15, n = 570), and the high ovarian response group (an AFC ≥ 15, n = 397), according to the AFC. The patients were sub-grouped according to LH levels on the protocol initiation day, and the clinical outcomes (including dose of Gn initiation, Gn administration days, GnRH-ant administration days, P levels on the HCG day, E2 levels on the HCG day, LH levels on the HCG day, number of embryos transferred, total fertilization rate, embryo implantation rate (%), proportion of 2PN, proportion of good-quality embryos, endometrial thickness on the hCG injection day (mm), moderate to severe OHSS, AFC on the initiation day, proportion of type A endometrium on the hCG injection day, clinical pregnancy rate, biochemical pregnancy rate, early abortion rate, ectopic pregnancy rate) were compared.
On the GnRH-A protocol initiation day, among all patients with different ovarian responses, the body mass index (BMI) in those with an LH ≥ 5 IU/L was lower. The difference of pregnancy outcome between the LH < 5 IU/L group and the LH ≥ 5 IU/L group were not statistically significant among the different ovarian response groups, but the LH < 5 IU/L group had a higher proportion of good-quality embryos (80.3 ± 24.9 vs. 74.8 ± 26.9, P =0.035) than the LH≥5IU/Lgroup in those with poor ovarian response. The total fertilization rate (82.2 ± 18.1 vs 85.4 ± 15.1, P =0.021) and proportion of two pronuclei (2PN) (69.0 ± 20.9 vs 72.7 ± 19.9, P =0.035) were higher in the LH ≥ 5 IU/L group than the LH<5 IU/L group for those with normal ovarian response. The embryo implantation rate (41.4 ± 41.3 vs 52.6 ± 43.4, P =0.012) was higher in the LH ≥ 5 IU/L group than in the LH<5 IU/L group in those with high ovarian response. The results of the multivariate logistic analysis showed that the age of the female partner, number of embryos transferred, proportion of good-quality embryos, endometrial thickness on the hCG injection day, and moderate-to-severe ovarian hyperstimulation syndrome (OHSS) were independent factors correlated with the outcome of live births (P < 0.05).
The LH levels on the gonadotropins (Gn) initiation day in GnRH-A protocol will not affect pregnancy outcomes.
本研究旨在探讨促性腺激素释放激素拮抗剂(GnRH-A)方案中促性腺激素起始的最佳时机以及黄体生成素(LH)水平的合理间隔。
进行一项回顾性队列研究,分析1361个体外受精/卵胞浆内单精子注射(IVF/ICSI)周期中接受GnRH-A方案治疗的不同卵巢反应患者的LH水平。根据窦卵泡计数(AFC)将这些患者的卵巢反应(包括抗缪勒管激素(AMH)、AFC)分为卵巢反应不良组(AFC≤6,n = 394)、卵巢反应正常组(AFC>6且<15,n = 570)和卵巢反应高组(AFC≥15,n = 397)。根据方案起始日的LH水平对患者进行亚组划分,并比较临床结局(包括促性腺激素起始剂量、促性腺激素给药天数、GnRH拮抗剂给药天数、HCG日的孕酮(P)水平、HCG日的雌二醇(E2)水平、HCG日的LH水平、移植胚胎数、总受精率、胚胎着床率(%)、双原核(2PN)比例、优质胚胎比例、HCG注射日的子宫内膜厚度(mm)、中度至重度卵巢过度刺激综合征(OHSS)、起始日的AFC、HCG注射日的A型子宫内膜比例、临床妊娠率、生化妊娠率、早期流产率、异位妊娠率)。
在GnRH-A方案起始日,在所有不同卵巢反应的患者中,LH≥5 IU/L者的体重指数(BMI)较低。在不同卵巢反应组中,LH<5 IU/L组和LH≥5 IU/L组之间的妊娠结局差异无统计学意义,但在卵巢反应不良者中,LH<5 IU/L组的优质胚胎比例(80.3±24.9 vs. 74.8±26.9,P = 0.035)高于LH≥5 IU/L组。在卵巢反应正常者中,LH≥5 IU/L组的总受精率(82.2±18.1 vs 85.4±15.1,P = 0.021)和双原核(2PN)比例((69.0±20.9 vs 72.7±19.9,P = 0.035)高于LH<5 IU/L组。在卵巢反应高者中,LH≥5 IU/L组的胚胎着床率(41.4±41.3 vs 52.6±43.4,P = 0.012)高于LH<5 IU/L组。多因素逻辑回归分析结果显示,女性伴侣年龄、移植胚胎数、优质胚胎比例、HCG注射日的子宫内膜厚度以及中度至重度卵巢过度刺激综合征(OHSS)是与活产结局相关的独立因素(P<0.05)。
GnRH-A方案中促性腺激素(Gn)起始日的LH水平不会影响妊娠结局。